ALPHAEON™ Acquires Exclusive License To Advanced Technology For Vision Correction

NEWPORT BEACH, Calif., Nov. 13, 2013 /PRNewswire/ -- ALPHAEON Corporation, a leader in lifestyle healthcare and wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired an exclusive U.S. license from SCHWIND eye-tech solutions GmbH & Co. KG to market the AMARIS^® excimer laser system, for an undisclosed amount. The state-of-the-art laser system, launched in 2007, is used in more than 120 countries worldwide and is a leader in laser vision correction procedures, including LASIK and surface ablation.

ALPHAEON Chief Executive Officer Robert E. Grant said, "Rolf Schwind and his management team have continued to innovate and advance laser technology to give people the best vision possible. The speed of their laser system and integration of wavefront and topographic data have led to impressive clinical outcomes internationally, and we believe the AMARIS system will represent leading-edge technology for lifestyle patients seeking vision correction."

President of ASCRS (American Society of Cataract and Refractive Surgery) Eric Donnenfeld M.D. said, "The SCHWIND excimer laser is an exciting technology that is considered state-of-the-art in Europe, but has not been available in the United States. ALPHAEON's determination to bring the SCHWIND laser to North America demonstrates its commitment to advancing technology and patient care."

SCHWIND Chief Executive Officer Rolf Schwind said, "We strongly believe that our partnership with ALPHAEON will build consumer confidence and significantly impact the growth of patient procedures."

Published data representing more than 10,000 eyes has demonstrated that 97 percent of all nearsighted patients treated with the AMARIS system achieved 20/20 or better unaided distance vision, when measured three months following treatment. As part of the relationship, ALPHAEON will oversee the U.S. Food and Drug Administration (FDA) clinical trial required to market the product in the United States.

ALPHAEON's licensing of the SCHWIND AMARIS excimer laser system marks the second ophthalmic licensing transaction and fifth overall transaction announced by the company since its corporate launch in July 2013. In August, ALPHAEON acquired the exclusive license to TEOXANE Laboratories' full portfolio of next-generation dermal fillers and cosmeceuticals, followed in October with the exclusive license to market EVOSYAL™, an advanced neurotoxin. In mid-October ALPHAEON acquired the exclusive right to market TouchMD™, a premier practice development platform and the Visiometrics S.L., HD Analyzer™, the first early cataract detection device.

"Each of the product and software transactions completed in the past 90 days fits seamlessly into ALPHAEON's strategy to lead the lifestyle healthcare market," said Mr. Grant.

ALPHAEON will begin commercializing products and services in January 2014. 

About ALPHAEON
ALPHAEON Corporation is a lifestyle healthcare company committed to partnering with board-certified physicians to bring to market and develop highly innovative technologies and services that promote patient wellness, beauty and performance. Ensuring access to leading advancements in lifestyle healthcare, the company fosters deep relationships with leading specialty physicians so patients look their best, feel their best and know they are receiving the best in lifestyle healthcare. For more information, please visit www.ALPHAEON.com.  

About Strathspey Crown
Strathspey Crown is a growth equity firm specializing in lifestyle healthcare. Strathspey Crown uniquely partners with board-certified physician specialists to bring to market highly innovative technologies and services in the self-pay sector. The firm is founded in partnership with physician investors across three key medical specialties: plastic surgery, ophthalmology and dermatology. For more information, please visit www.strathspeycrown.com.

About SCHWIND eye-tech solutions
Founded in 1958, SCHWIND eye-tech solutions is a privately held manufacturer of ophthalmic laser systems with presence in more than 120 countries. Its alliance with ALPHAEON will bring its full line of products to market in the United States. For more information, please visit www.eye-tech-solutions.com.

PRESS CONTACTS:
Jenna Mons, Director of Marketing and Communications
Tel: +1 949.260.1700
Email: [email protected]

ALPHAEON™ is a trademark of ALPHAEON
SCHWIND AMARIS^® is a registered trademark of SCHWIND eye-tech solutions
EVOSYAL^™ is a trademark of Strathspey Crown LLC
TouchMD^™ is a trademark of TouchMD
HD Analyzer^™ is a trademark of Visiometrics

SOURCE ALPHAEON Corporation